15 related articles for article (PubMed ID: 38713217)
1. Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
Tachiki LML; Hippe DS; Williams Silva K; Hall ET; McCamy W; Fritzsche D; Perdue A; Majovski J; Pulliam T; Goldstein DA; Veatch J; Ho J; Nghiem PT; Thompson JA; Bhatia S
Cancer Immunol Immunother; 2023 Nov; 72(11):3839-3850. PubMed ID: 37733060
[TBL] [Abstract][Full Text] [Related]
2. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; van Akkooi A; Bataille V; Bastholt L; Dreno B; Dummer R; Fargnoli MC; Forsea AM; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Lallas A; Leiter U; Malvehy J; Del Marmol V; Moreno-Ramirez D; Pellacani G; Peris K; Saiag P; Tagliaferri L; Trakatelli M; Ioannides D; Vieira R; Zalaudek I; Arenberger P; Eggermont AMM; Röcken M; Grob JJ; Lorigan P;
Eur J Cancer; 2023 Nov; 193():113251. PubMed ID: 37717283
[TBL] [Abstract][Full Text] [Related]
3. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; van Akkooi A; Bataille V; Bastholt L; Dreno B; Dummer R; Fargnoli MC; Forsea AM; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Lallas A; Leiter U; Malvehy J; Del Marmol V; Moreno-Ramirez D; Pellacani G; Peris K; Saiag P; Tagliaferri L; Trakatelli M; Ioannides D; Vieira R; Zalaudek I; Arenberger P; Eggermont AMM; Röcken M; Grob JJ; Lorigan P;
Eur J Cancer; 2023 Nov; 193():113252. PubMed ID: 37708630
[TBL] [Abstract][Full Text] [Related]
4. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study.
Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Kaufman HL; Seebach F; Lowy I; Yoo SY; Mathias M; Fenech K; Han H; Fury MG; Rischin D
N Engl J Med; 2022 Oct; 387(17):1557-1568. PubMed ID: 36094839
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant radiation following clear margin resection of high T-stage cutaneous squamous cell carcinoma halves the risk of local and locoregional recurrence: A dual-center retrospective study.
Ruiz ES; Kus KJB; Smile TD; Murad F; Zhou G; Ilori EO; Schoenfeld JD; Margalit DN; Tishler RB; Vidimos AT; Koyfman SA; Schmults CD
J Am Acad Dermatol; 2022 Jul; 87(1):87-94. PubMed ID: 35364211
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant radiotherapy may not significantly change outcomes in high-risk cutaneous squamous cell carcinomas with clear surgical margins: A systematic review and meta-analysis.
Kim Y; Lehrer EJ; Wirth PJ; Khesroh EA; Brewer JD; Billingsley EM; Zaorsky NG; Lam C
J Am Acad Dermatol; 2022 Jun; 86(6):1246-1257. PubMed ID: 34890701
[TBL] [Abstract][Full Text] [Related]
8. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
9. Cemiplimab for Locally Advanced and Metastatic Cutaneous Squamous-Cell Carcinomas: Real-Life Experience from the French CAREPI Study Group.
Hober C; Fredeau L; Pham-Ledard A; Boubaya M; Herms F; Celerier P; Aubin F; Beneton N; Dinulescu M; Jannic A; Meyer N; Duval-Modeste AB; Cesaire L; Neidhardt ÈM; Archier É; Dréno B; Lesage C; Berthin C; Kramkimel N; Grange F; de Quatrebarbes J; Stoebner PE; Poulalhon N; Arnault JP; Abed S; Bonniaud B; Darras S; Heidelberger V; Devaux S; Moncourier M; Misery L; Mansard S; Etienne M; Brunet-Possenti F; Jacobzone C; Lesbazeilles R; Skowron F; Sanchez J; Catala S; Samimi M; Tazi Y; Spaeth D; Gaudy-Marqueste C; Collard O; Triller R; Pracht M; Dumas M; Peuvrel L; Combe P; Lauche O; Guillet P; Reguerre Y; Kupfer-Bessaguet I; Solub D; Schoeffler A; Bedane C; Quéreux G; Dalac S; Mortier L; Maubec È
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298764
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in Older Adults With Cancer.
Presley CJ; Gomes F; Burd CE; Kanesvaran R; Wong ML
J Clin Oncol; 2021 Jul; 39(19):2115-2127. PubMed ID: 34043444
[No Abstract] [Full Text] [Related]
11. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival after anti-PD-1 discontinuation in advanced cutaneous squamous cell carcinoma (cSCC): a proof of concept of benefit of concomitant cemiplimab and radiotherapy.
Bailly-Caillé B; Levard R; Kottler D; Dompmartin A; L'Orphelin JM
Cancer Immunol Immunother; 2024 May; 73(7):118. PubMed ID: 38713217
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
